Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: Implications for biological regulation of 5-lipoxygenase

This publication has 28 references indexed in Scilit:

• Role of 5-lipoxygenase-activating protein in the regulation of 5-lipoxygenase activity in human neutrophils
  Inflammation Research, 1994
• Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein
  European Journal of Pharmacology: Molecular Pharmacology, 1994
• Redistribution of 5-Lipoxygenase and Cytosolic Phospholipase A2 to the Nuclear Fraction upon Macrophage Activation
  Biochemical and Biophysical Research Communications, 1993
• 5‐lipoxygenase‐activating protein is an arachidonate binding protein
  FEBS Letters, 1993
• In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis
  Inflammation Research, 1993
• A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells.
  The Journal of cell biology, 1992
• FLAP: a novel drug target for inhibiting the synthesis of leukotrienes
  Trends in Pharmacological Sciences, 1991
• Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis
  Nature, 1990
• Identification and isolation of a membrane protein necessary for leukotriene production
  Nature, 1990
• L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor
  Canadian Journal of Physiology and Pharmacology, 1989